Home » Newsletters » BioWorld Science

BioWorld Science

June 16, 2015

View Archived Issues

IMAB-027 safe and well tolerated in first study in humans

Lilly presents clinical data on anti-GCGR MAb for diabetes

First clinical results for nAChR tracer [18F]XTRA

Corbus Pharmaceuticals' Resunab receives FDA orphan drug designation for systemic sclerosis

AnGes reports results of pilot study of Ebola vaccine

DRAM2 mutations linked to retinal dystrophy with early macular degeneration

Cellmid's CAB-102 shown to be safe in toxicology studies

Circadian Technologies receives approval from FDA to initiate trial of OPT-302

Genzyme starts phase I/II trial of olipudase alfa in children with Niemann-Pick disease

PlasmaTech licenses Fanconi anemia gene therapy and CRISPR gene-editing technology

Avalanche Biotechnologies reports phase IIa findings for AVA-101 in wet AMD

U.S. researchers patent new antivirals

Laurent Pharmaceuticals' Lau-7b is safe and well tolerated in patients with cystic fibrosis

Pharmascience describes BTK inhibitors

Universiteit Ghent discloses peloruside analogues

Spanish scientists report vitamin D analogues

Sunshine Lake Pharma develops anti-HBV agents

RedHill Biopharma's RHB-105 meets primary endpoint in phase III H. pylori infection trial

Neovacs launches clinical development program in dermatomyositis

BioBlast initiates phase III study of Cabaletta in oculopharyngeal muscular dystrophy

Atara Biotherapeutics exercises option to T-cell technology from MSK

FDA accepts Teva's BLA for reslizumab in asthma with elevated eosinophil levels

Chiasma files NDA for oral octreotide in acromegaly

Pre-EUA dossier for Cleveland Biolabs' entolimod submitted to FDA

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 16, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 16, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.